1-3 of 3
Ute Hegenbart
Close
Sort by
Journal Articles

Search for AL amyloidosis risk factors using Mendelian randomization

Charlie N. Saunders, Subhayan Chattopadhyay, Stefanie Huhn, Niels Weinhold, Per Hoffmann, Markus M. Nöthen, Karl-Heinz Jöckel, Börge Schmidt, Stefano Landi, Hartmut Goldschmidt, Paolo Milani, Giampaolo Merlini, Dorota Rowcieno, Philip Hawkins, Ute Hegenbart, Giovanni Palladini, Ashutosh Wechalekar, Stefan O. Schönland, Asta Försti, Richard Houlston, Kari Hemminki
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2725–2731.
https://doi.org/10.1182/bloodadvances.2021004423
Published: 2021
Includes: Supplemental data
Journal Articles

CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Clinical Trials & Observations
Peter Dreger, Sascha Dietrich, Maria-Luisa Schubert, Lorenz Selberg, Andrea Bondong, Mandy Wegner, Peter Stadtherr, Christoph Kimmich, Florentina Kosely, Anita Schmitt, Petra Pavel, Nora Liebers, Thomas Luft, Ute Hegenbart, Aleksandar Radujkovic, Anthony Dick Ho, Carsten Müller-Tidow, Michael Schmitt
Journal: Blood Advances
Blood Adv (2020) 4 (24): 6157–6168.
https://doi.org/10.1182/bloodadvances.2020003036
Published: 2020
Includes: Supplemental data
Journal Articles

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma

Tilmann Bochtler, Maximilian Merz, Thomas Hielscher, Martin Granzow, Korbinian Hoffmann, Alwin Krämer, Marc-Steffen Raab, Jens Hillengass, Anja Seckinger, Christoph Kimmich, Tobias Dittrich, Carsten Müller-Tidow, Dirk Hose, Hartmut Goldschmidt, Ute Hegenbart, Anna Jauch, Stefan O. Schönland
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2607–2618.
https://doi.org/10.1182/bloodadvances.2018023200
Published: 2018
Includes: Supplemental data